Neuraminidase-based recombinant virus-like particles protect against lethal avian influenza A(H5N1) virus infection in ferrets
Identifieur interne : 000807 ( Pmc/Corpus ); précédent : 000806; suivant : 000808Neuraminidase-based recombinant virus-like particles protect against lethal avian influenza A(H5N1) virus infection in ferrets
Auteurs : Gale E. Smith ; Xiangjie Sun ; Yaohui Bai ; Ye V. Liu ; Michael J. Massare ; Melissa B. Pearce ; Jessica A. Belser ; Taronna R. Maines ; Hannah M. Creager ; Gregory M. Glenn ; David Flyer ; Peter Pushko ; Min Z. Levine ; Terrence M. TumpeySource :
- Virology [ 0042-6822 ] ; 2017.
Abstract
Avian influenza A (H5N1) viruses represent a growing threat for an influenza pandemic. The presence of widespread avian influenza virus infections further emphasizes the need for vaccine strategies for control of prepandemic H5N1 and other avian influenza subtypes. Influenza neuraminidase (NA) vaccines represent a potential strategy for improving vaccines against avian influenza H5N1 viruses. To evaluate a strategy for NA vaccination, we generated a recombinant influenza virus-like particle (VLP) vaccine comprised of the NA protein of A/Indonesia/05/2005 (H5N1) virus. Ferrets vaccinated with influenza N1 NA VLPs elicited high-titer serum NA-inhibition (NI) antibody titers and were protected from lethal challenge with A/Indonesia/05/2005 virus. Moreover, N1-immune ferrets shed less infectious virus than similarly challenged control animals. In contrast, ferrets administered control N2 NA VLPs were not protected against H5N1 virus challenge. These results provide support for continued development of NA-based vaccines against influenza H5N1 viruses.
Url:
DOI: 10.1016/j.virol.2017.06.006
PubMed: 28624679
PubMed Central: 5788299
Links to Exploration step
PMC:5788299Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neuraminidase-based recombinant virus-like particles protect against lethal avian influenza A(H5N1) virus infection in ferrets</title><author><name sortKey="Smith, Gale E" sort="Smith, Gale E" uniqKey="Smith G" first="Gale E." last="Smith">Gale E. Smith</name><affiliation><nlm:aff id="A1">Novavax, Inc., 20 Firstfield, Gaithersburg, MD 20878, USA</nlm:aff></affiliation></author><author><name sortKey="Sun, Xiangjie" sort="Sun, Xiangjie" uniqKey="Sun X" first="Xiangjie" last="Sun">Xiangjie Sun</name><affiliation><nlm:aff id="A3">Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA</nlm:aff></affiliation></author><author><name sortKey="Bai, Yaohui" sort="Bai, Yaohui" uniqKey="Bai Y" first="Yaohui" last="Bai">Yaohui Bai</name><affiliation><nlm:aff id="A3">Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA</nlm:aff></affiliation></author><author><name sortKey="Liu, Ye V" sort="Liu, Ye V" uniqKey="Liu Y" first="Ye V." last="Liu">Ye V. Liu</name><affiliation><nlm:aff id="A1">Novavax, Inc., 20 Firstfield, Gaithersburg, MD 20878, USA</nlm:aff></affiliation></author><author><name sortKey="Massare, Michael J" sort="Massare, Michael J" uniqKey="Massare M" first="Michael J." last="Massare">Michael J. Massare</name><affiliation><nlm:aff id="A1">Novavax, Inc., 20 Firstfield, Gaithersburg, MD 20878, USA</nlm:aff></affiliation></author><author><name sortKey="Pearce, Melissa B" sort="Pearce, Melissa B" uniqKey="Pearce M" first="Melissa B." last="Pearce">Melissa B. Pearce</name><affiliation><nlm:aff id="A3">Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA</nlm:aff></affiliation></author><author><name sortKey="Belser, Jessica A" sort="Belser, Jessica A" uniqKey="Belser J" first="Jessica A." last="Belser">Jessica A. Belser</name><affiliation><nlm:aff id="A3">Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA</nlm:aff></affiliation></author><author><name sortKey="Maines, Taronna R" sort="Maines, Taronna R" uniqKey="Maines T" first="Taronna R." last="Maines">Taronna R. Maines</name><affiliation><nlm:aff id="A3">Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA</nlm:aff></affiliation></author><author><name sortKey="Creager, Hannah M" sort="Creager, Hannah M" uniqKey="Creager H" first="Hannah M." last="Creager">Hannah M. Creager</name><affiliation><nlm:aff id="A3">Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA</nlm:aff></affiliation><affiliation><nlm:aff id="A4">Microbiology and Molecular Genetics Graduate Program, Emory University, Atlanta, GA, USA</nlm:aff></affiliation></author><author><name sortKey="Glenn, Gregory M" sort="Glenn, Gregory M" uniqKey="Glenn G" first="Gregory M." last="Glenn">Gregory M. Glenn</name><affiliation><nlm:aff id="A1">Novavax, Inc., 20 Firstfield, Gaithersburg, MD 20878, USA</nlm:aff></affiliation></author><author><name sortKey="Flyer, David" sort="Flyer, David" uniqKey="Flyer D" first="David" last="Flyer">David Flyer</name><affiliation><nlm:aff id="A1">Novavax, Inc., 20 Firstfield, Gaithersburg, MD 20878, USA</nlm:aff></affiliation></author><author><name sortKey="Pushko, Peter" sort="Pushko, Peter" uniqKey="Pushko P" first="Peter" last="Pushko">Peter Pushko</name><affiliation><nlm:aff id="A2">Medigen, Inc., 8420 Gas House Pike, Frederick, MD, USA</nlm:aff></affiliation></author><author><name sortKey="Levine, Min Z" sort="Levine, Min Z" uniqKey="Levine M" first="Min Z." last="Levine">Min Z. Levine</name><affiliation><nlm:aff id="A3">Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA</nlm:aff></affiliation></author><author><name sortKey="Tumpey, Terrence M" sort="Tumpey, Terrence M" uniqKey="Tumpey T" first="Terrence M." last="Tumpey">Terrence M. Tumpey</name><affiliation><nlm:aff id="A3">Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">28624679</idno><idno type="pmc">5788299</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788299</idno><idno type="RBID">PMC:5788299</idno><idno type="doi">10.1016/j.virol.2017.06.006</idno><date when="2017">2017</date><idno type="wicri:Area/Pmc/Corpus">000807</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000807</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Neuraminidase-based recombinant virus-like particles protect against lethal avian influenza A(H5N1) virus infection in ferrets</title><author><name sortKey="Smith, Gale E" sort="Smith, Gale E" uniqKey="Smith G" first="Gale E." last="Smith">Gale E. Smith</name><affiliation><nlm:aff id="A1">Novavax, Inc., 20 Firstfield, Gaithersburg, MD 20878, USA</nlm:aff></affiliation></author><author><name sortKey="Sun, Xiangjie" sort="Sun, Xiangjie" uniqKey="Sun X" first="Xiangjie" last="Sun">Xiangjie Sun</name><affiliation><nlm:aff id="A3">Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA</nlm:aff></affiliation></author><author><name sortKey="Bai, Yaohui" sort="Bai, Yaohui" uniqKey="Bai Y" first="Yaohui" last="Bai">Yaohui Bai</name><affiliation><nlm:aff id="A3">Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA</nlm:aff></affiliation></author><author><name sortKey="Liu, Ye V" sort="Liu, Ye V" uniqKey="Liu Y" first="Ye V." last="Liu">Ye V. Liu</name><affiliation><nlm:aff id="A1">Novavax, Inc., 20 Firstfield, Gaithersburg, MD 20878, USA</nlm:aff></affiliation></author><author><name sortKey="Massare, Michael J" sort="Massare, Michael J" uniqKey="Massare M" first="Michael J." last="Massare">Michael J. Massare</name><affiliation><nlm:aff id="A1">Novavax, Inc., 20 Firstfield, Gaithersburg, MD 20878, USA</nlm:aff></affiliation></author><author><name sortKey="Pearce, Melissa B" sort="Pearce, Melissa B" uniqKey="Pearce M" first="Melissa B." last="Pearce">Melissa B. Pearce</name><affiliation><nlm:aff id="A3">Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA</nlm:aff></affiliation></author><author><name sortKey="Belser, Jessica A" sort="Belser, Jessica A" uniqKey="Belser J" first="Jessica A." last="Belser">Jessica A. Belser</name><affiliation><nlm:aff id="A3">Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA</nlm:aff></affiliation></author><author><name sortKey="Maines, Taronna R" sort="Maines, Taronna R" uniqKey="Maines T" first="Taronna R." last="Maines">Taronna R. Maines</name><affiliation><nlm:aff id="A3">Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA</nlm:aff></affiliation></author><author><name sortKey="Creager, Hannah M" sort="Creager, Hannah M" uniqKey="Creager H" first="Hannah M." last="Creager">Hannah M. Creager</name><affiliation><nlm:aff id="A3">Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA</nlm:aff></affiliation><affiliation><nlm:aff id="A4">Microbiology and Molecular Genetics Graduate Program, Emory University, Atlanta, GA, USA</nlm:aff></affiliation></author><author><name sortKey="Glenn, Gregory M" sort="Glenn, Gregory M" uniqKey="Glenn G" first="Gregory M." last="Glenn">Gregory M. Glenn</name><affiliation><nlm:aff id="A1">Novavax, Inc., 20 Firstfield, Gaithersburg, MD 20878, USA</nlm:aff></affiliation></author><author><name sortKey="Flyer, David" sort="Flyer, David" uniqKey="Flyer D" first="David" last="Flyer">David Flyer</name><affiliation><nlm:aff id="A1">Novavax, Inc., 20 Firstfield, Gaithersburg, MD 20878, USA</nlm:aff></affiliation></author><author><name sortKey="Pushko, Peter" sort="Pushko, Peter" uniqKey="Pushko P" first="Peter" last="Pushko">Peter Pushko</name><affiliation><nlm:aff id="A2">Medigen, Inc., 8420 Gas House Pike, Frederick, MD, USA</nlm:aff></affiliation></author><author><name sortKey="Levine, Min Z" sort="Levine, Min Z" uniqKey="Levine M" first="Min Z." last="Levine">Min Z. Levine</name><affiliation><nlm:aff id="A3">Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA</nlm:aff></affiliation></author><author><name sortKey="Tumpey, Terrence M" sort="Tumpey, Terrence M" uniqKey="Tumpey T" first="Terrence M." last="Tumpey">Terrence M. Tumpey</name><affiliation><nlm:aff id="A3">Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA</nlm:aff></affiliation></author></analytic><series><title level="j">Virology</title><idno type="ISSN">0042-6822</idno><idno type="eISSN">1096-0341</idno><imprint><date when="2017">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p id="P1">Avian influenza A (H5N1) viruses represent a growing threat for an influenza pandemic. The presence of widespread avian influenza virus infections further emphasizes the need for vaccine strategies for control of prepandemic H5N1 and other avian influenza subtypes. Influenza neuraminidase (NA) vaccines represent a potential strategy for improving vaccines against avian influenza H5N1 viruses. To evaluate a strategy for NA vaccination, we generated a recombinant influenza virus-like particle (VLP) vaccine comprised of the NA protein of A/Indonesia/05/2005 (H5N1) virus. Ferrets vaccinated with influenza N1 NA VLPs elicited high-titer serum NA-inhibition (NI) antibody titers and were protected from lethal challenge with A/Indonesia/05/2005 virus. Moreover, N1-immune ferrets shed less infectious virus than similarly challenged control animals. In contrast, ferrets administered control N2 NA VLPs were not protected against H5N1 virus challenge. These results provide support for continued development of NA-based vaccines against influenza H5N1 viruses.</p></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">0110674</journal-id><journal-id journal-id-type="pubmed-jr-id">8015</journal-id><journal-id journal-id-type="nlm-ta">Virology</journal-id><journal-id journal-id-type="iso-abbrev">Virology</journal-id><journal-title-group><journal-title>Virology</journal-title></journal-title-group><issn pub-type="ppub">0042-6822</issn><issn pub-type="epub">1096-0341</issn></journal-meta><article-meta><article-id pub-id-type="pmid">28624679</article-id><article-id pub-id-type="pmc">5788299</article-id><article-id pub-id-type="doi">10.1016/j.virol.2017.06.006</article-id><article-id pub-id-type="manuscript">HHSPA936872</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Neuraminidase-based recombinant virus-like particles protect against lethal avian influenza A(H5N1) virus infection in ferrets</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Smith</surname><given-names>Gale E.</given-names></name><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Xiangjie</given-names></name><xref ref-type="aff" rid="A3">c</xref></contrib><contrib contrib-type="author"><name><surname>Bai</surname><given-names>Yaohui</given-names></name><xref ref-type="aff" rid="A3">c</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Ye V.</given-names></name><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name><surname>Massare</surname><given-names>Michael J.</given-names></name><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name><surname>Pearce</surname><given-names>Melissa B.</given-names></name><xref ref-type="aff" rid="A3">c</xref></contrib><contrib contrib-type="author"><name><surname>Belser</surname><given-names>Jessica A.</given-names></name><xref ref-type="aff" rid="A3">c</xref></contrib><contrib contrib-type="author"><name><surname>Maines</surname><given-names>Taronna R.</given-names></name><xref ref-type="aff" rid="A3">c</xref></contrib><contrib contrib-type="author"><name><surname>Creager</surname><given-names>Hannah M.</given-names></name><xref ref-type="aff" rid="A3">c</xref><xref ref-type="aff" rid="A4">d</xref></contrib><contrib contrib-type="author"><name><surname>Glenn</surname><given-names>Gregory M.</given-names></name><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name><surname>Flyer</surname><given-names>David</given-names></name><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name><surname>Pushko</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="A2">b</xref></contrib><contrib contrib-type="author"><name><surname>Levine</surname><given-names>Min Z.</given-names></name><xref ref-type="aff" rid="A3">c</xref></contrib><contrib contrib-type="author"><name><surname>Tumpey</surname><given-names>Terrence M.</given-names></name><xref ref-type="aff" rid="A3">c</xref><xref rid="FN1" ref-type="author-notes">*</xref></contrib></contrib-group><aff id="A1"><label>a</label>Novavax, Inc., 20 Firstfield, Gaithersburg, MD 20878, USA</aff><aff id="A2"><label>b</label>Medigen, Inc., 8420 Gas House Pike, Frederick, MD, USA</aff><aff id="A3"><label>c</label>Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA</aff><aff id="A4"><label>d</label>Microbiology and Molecular Genetics Graduate Program, Emory University, Atlanta, GA, USA</aff><author-notes><corresp id="FN1"><label>*</label>Correspondence to: Influenza Division, MS G-16, 1600 Clifton Rd. NE, Atlanta, GA 30329, USA. <email>TTumpey@cdc.gov</email> (T.M. Tumpey)</corresp></author-notes><pub-date pub-type="nihms-submitted"><day>24</day><month>1</month><year>2018</year></pub-date><pub-date pub-type="epub"><day>16</day><month>6</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>9</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>29</day><month>1</month><year>2018</year></pub-date><volume>509</volume><fpage>90</fpage><lpage>97</lpage><pmc-comment>elocation-id from pubmed: 10.1016/j.virol.2017.06.006</pmc-comment>
<abstract><p id="P1">Avian influenza A (H5N1) viruses represent a growing threat for an influenza pandemic. The presence of widespread avian influenza virus infections further emphasizes the need for vaccine strategies for control of prepandemic H5N1 and other avian influenza subtypes. Influenza neuraminidase (NA) vaccines represent a potential strategy for improving vaccines against avian influenza H5N1 viruses. To evaluate a strategy for NA vaccination, we generated a recombinant influenza virus-like particle (VLP) vaccine comprised of the NA protein of A/Indonesia/05/2005 (H5N1) virus. Ferrets vaccinated with influenza N1 NA VLPs elicited high-titer serum NA-inhibition (NI) antibody titers and were protected from lethal challenge with A/Indonesia/05/2005 virus. Moreover, N1-immune ferrets shed less infectious virus than similarly challenged control animals. In contrast, ferrets administered control N2 NA VLPs were not protected against H5N1 virus challenge. These results provide support for continued development of NA-based vaccines against influenza H5N1 viruses.</p></abstract><kwd-group><kwd>VLP vaccine</kwd><kwd>H5N1 influenza</kwd><kwd>Ferret</kwd><kwd>Neuraminidase (NA)</kwd></kwd-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000807 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000807 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:5788299
|texte= Neuraminidase-based recombinant virus-like particles protect against lethal avian influenza A(H5N1) virus infection in ferrets
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:28624679" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |